Arcutis Biotherapeutics grants 143,500 RSUs, 37,000 stock options to new hires under inducement plan

Arcutis Biotherapeutics granted 143,500 restricted stock units and 37,000 stock options to 24 newly hired employees under its 2022 Inducement Plan.

• The RSUs vest over four years, with 25% vesting on each annual anniversary, subject to continued employment.
• The options vest over four years; 25% vests after one year, with the remainder vesting in equal monthly installments over three years.
• The options carry a 10-year term, with an exercise price of $25.94 per share, set on Aug. 3, 2026.